Abstract
Oncomine Dx Target Test Multi CDx system (ODxTT) was reimbursed in Japan in 2019, and the second half of 2019 was a transitional period for clinical introduction. There was a concern that time from test to treatment introduction (TTT) might be longer than that of simultaneous single tests in clinical practice at the time of initial phase of introducing . However, TTT of ODxTT was revealed to be comparable with that of simultaneous single companion diagnostics (CDx) tests (JSMO2021). In this report, we updated the current status of lung cancer CDx in Japanese clinical practice.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
